ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Fibrous ingrowth: an overlooked cause of Ahmed Glaucoma Valve failure.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo highlight fibrous ingrowth (FI) into the Ahmed Glaucoma Valve (AGV) mechanism as a previously under-recognized cause of late AGV failure.
methodsIn this prospective interventional case series, 40 eyes of 40 patients with failed AGVs underwent capsulectomy shunt revision (CSR) between September 2022 and October 2024. The cohort included a high proportion of congenital and juvenile glaucoma cases, reflecting the tertiary referral nature of our center. Intraoperatively, the AGV valve mechanism was thoroughly explored, with special attention to identifying growth of fibrous tissue into the valve chamber. After the procedures, patients were stratified into two groups: those with fibrous ingrowth (FI-CSR) and those without abnormal ingrowth (CSR). Pre- and postoperative intraocular pressure (IOP), number of medications, complications and surgical success were reported. Histopathologic evaluation was performed on the excised tissue in the FI-CSR group.
resultsFI was identified in 30% (12/40) of all operated eyes. Patients in the FI-CSR group were significantly older (26.3 ± 20.4 versus 16.6 ± 10.2 years old, P = 0.049) and had undergone a larger number of prior surgeries (3.8 ± 1.3 versus 2.1 ± 1.3 procedures, P < 0.001). The prevalence of primary congenital glaucoma (PCG) was also significantly higher in the FI-CSR group as compared to the CSR group (8/12 [66.7%] versus 11/28 [39.3%] cases respectively, P < 0.001). At 12 months after surgical revision, mean IOP decreased from 28.1 ± 6.8 mmHg to 15.1 ± 2.1 mmHg in the FI-CSR group (P < 0.001) and from 28.1 ± 5.9 to 16.9 ± 4.4 mmHg in the CSR group (P < 0.001). Final IOP and surgical success rates at 12 months were comparable between the two groups. No vision-threatening complications were observed during the follow-up period. Histopathologic evaluation of the excised FI tissue revealed dense fibrovascular tissue with chronic inflammation.
conclusionFibrous ingrowth into the AGV valve chamber is a significant but often overlooked cause of AGV failure. Surgical excision of FI during CSR was associated with restored device function and improved IOP control with outcomes comparable to conventional CSR. Exploration of the valve mechanism for detection and removal of FI is beneficial during revision procedures in eyes with failed AGVs and could avoid more invasive interventions.
Indexed as
Identifiers
41762270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.